AstraZeneca has seen around £20 billion wiped from its market value following the disappointing late-stage trial results for Wainua, pushing its market capitalisation below £200 billion.
Avacta cuts convertible bond debt with £3.67m payment
Accelerated Amortized Payment of Convertible Bond Installment
Physiomics (AIM: PYC) Awarded Multiple New Contracts
Physiomics plc (AIM: PYC) has secured multiple new contract awards with a combined estimated value of more than £200,000.
Avacta Appoints Patrick Vink as Deputy Chairman
Avacta Therapeutics (AIM: AVCT) has appointed healthcare executive Dr Patrick Vink to its board as non-executive deputy chairman and senior independent director.
Physiomics plc (AIM: PYC) Appointment of Chief Operating Officer
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the promotion of
South African approval boosts POLB intellectual property
POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza Patent decision strengthens Poolbeg’s intellectual property portfolio
genedrive partners with Thermo Fisher on NHS testing
genedrive plc (AIM: GDR) has entered into a product development collaboration with Thermo Fisher Scientific to develop a high-throughput CYP2C19 pharmacogenetic test for deployment on Thermo Fisher’s QuantStudio™ 5 Dx
Scancell confirms advanced reverse merger talks with US-listed Neuphoria
Scancell: Response to Press Speculation
Physiomics strengthens outlook with cost savings and pipeline growth
Physiomics (AIM: PYC) has provided a positive operational update, highlighting record commercial opportunities, cost savings and a clearer path towards profitability as the AIM-listed modelling and data science specialist executes
Avacta advances AVA6000 towards pivotal US trial
Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer
ImmuPharma highlights brain cancer potential for P140
ImmuPharma (AIM: IMM) has highlighted new academic research suggesting its lead drug candidate, P140, may have potential as a treatment for glioblastoma, one of the most aggressive and difficult-to-treat forms
Shareholders give overwhelming support to Avacta proposals
Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.